Head to Head Analysis: Silexion Therapeutics (SLXN) vs. The Competition

Silexion Therapeutics (NASDAQ:SLXN) is one of 618 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it compare to its peers? We will compare Silexion Therapeutics to related companies based on the strength of its dividends, institutional ownership, analyst recommendations, earnings, profitability, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Silexion Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1	0	1	0	2.00
Silexion Therapeutics Competitors	5230	11875	36981	1106	2.62

Silexion Therapeutics presently has a consensus target price of $75.00, suggesting a potential upside of 2,080.23%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 62.52%. Given Silexion Therapeutics’ higher probable upside, research analysts clearly believe Silexion Therapeutics is more favorable than its peers.

Earnings and Valuation

This table compares Silexion Therapeutics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Silexion Therapeutics	N/A	-$16.44 million	-0.01
Silexion Therapeutics Competitors	$884.54 million	-$46.13 million	-2.73

Silexion Therapeutics’ peers have higher revenue, but lower earnings than Silexion Therapeutics. Silexion Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 51.1% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 6.0% of Silexion Therapeutics shares are held by insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Silexion Therapeutics has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500. Comparatively, Silexion Therapeutics’ peers have a beta of 0.97, suggesting that their average share price is 3% less volatile than the S&P 500.

Profitability

This table compares Silexion Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	N/A	-355.74%
Silexion Therapeutics Competitors	-1,402.81%	-643.20%	-28.35%

Summary

Silexion Therapeutics peers beat Silexion Therapeutics on 8 of the 13 factors compared.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.